Please add the following new claims to the application:

63. (New) A method for delivery of a drug to a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core to said selected site.

64. (New) The method of claim 63 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

65. (New) The method of claim 63 wherein said drug is hydrophobic.

66. (New) The method of claim 65 wherein said hydrophobic drug is an anthracycline.

67. (New) The method of claim 66 wherein said anthracycline is doxorubicin.

68. (New) The method of claim 66 wherein said anthracycline is ruboxyl.

69. (New) A composition for delivery of a hydrophobic drug to a selected site in a patient comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said hydrophobic drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer.

70. (New) The composition of claim 69 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

71. (New) The composition of claim 69 wherein said hydrophobic drug is an anthracycline.

72. (New) The composition of claim 71 wherein said anthracycline is doxorubicin.

73. (New) The composition of claim 71 wherein said anthracycline is ruboxyl.

74. (New) A method for enhancing uptake of a drug by cells at a selected site in a patient comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said selected site such that said drug is released from said hydrophobic core and taken up by said cells.

75. (New) The method of claim 74 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

76. (New) The method of claim 74 wherein said drug is hydrophobic.

77. (New) The method of claim 76 wherein said hydrophobic drug is an anthracycline.

78. (New) The method of claim 77 wherein said anthracycline is doxorubicin.

79. (New) The method of claim 77 wherein said anthracycline is ruboxyl.

80. (New) A method for reducing side effects in a patient from administration of a drug comprising:

(a) administering to said patient a composition comprising a micellar drug carrier comprising a hydrophobic core and an effective amount of said drug disposed in said hydrophobic core, wherein said micellar drug carrier is an AB-diblock copolymer; and

(b) applying ultrasonic energy to said patient such that said drug is released from said hydrophobic core.

81. (New) The method of claim 80 wherein said AB-diblock copolymer comprises poly(L-amino acid)-co-poly(ethylene oxide).

82. (New) The method of claim 80 wherein said drug is hydrophobic.

83. (New) The method of claim 82 wherein said hydrophobic drug is an anthracycline.

84. (New) The method of claim 83 wherein said anthracycline is doxorubicin.